业务进展情况 研发管线关键里程碑：诺华正处于密集的研发周期，2026年预计将有7项关键数据读出，未来两年内可 能有超过15项潜在上市申报或关键数据读出，涉及30多个高价值管线资产。具体而言，公司预告2026年 将有28项监管申请递交或批准、9项重要研究读出数据以及6项关键研究启动。这些事件覆盖心血管、肿 瘤、免疫和神经科学等领域。 战略推进 并购与业务拓展活动：诺华首席执行官万思瀚强调，公司将继续通过单笔金额不超过20亿美元的早期交 易充实研发管线，同时积极寻找后期阶段资产，尤其是未来五年内有望上市的品种。近期案例包括对 Avidity、Tourmaline等公司的收购，这类交易可能持续影响管线布局。 近期公司状况 经济观察网 基于2026年2月发布的诺华最新财报和战略展望，以下是诺华制药股票在2026年及近期可能 值得关注的事件摘要。这些信息主要来源于公司官方公告和财经媒体报道。 近期事件 2026年财务业绩与股息计划：诺华管理层在2026年战略展望中预计，全年净销售额将实现低个位数增 长，但核心营业收入可能下降低个位数。公司计划在2026年派发每股3.70瑞士法郎的股息，按瑞士法郎 计算同比增长。首席财务 ...

Core Points - Novartis announced the expiration of its tender offer to acquire Tourmaline Bio, Inc. at a price of $48.00 per share, which ended on October 27, 2025 [1][2] - Approximately 24,030,382 shares were validly tendered, representing about 92.94% of the outstanding shares prior to the expiration [2] Company Information - Novartis is an innovative medicines company focused on improving and extending lives through its products, reaching over 300 million people globally [5]

Core Points - Novartis announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in relation to its tender offer to acquire Tourmaline Bio at a price of $48.00 per share in cash [1][2] - The expiration of the HSR Act waiting period is a necessary condition for the completion of the merger agreement dated September 8, 2025, which includes the tender offer and subsequent merger [2] - The tender offer will expire at 11:59 p.m. Eastern Time on October 27, 2025, unless extended or terminated earlier [2] Company Information - Novartis is an innovative medicines company focused on improving and extending people's lives through its products, reaching over 300 million people globally [7]

Core Insights - Novartis announced positive final results from the late-stage APPLAUSE-IgAN study on Fabhalta (iptacopan) for adults with IgA nephropathy (IgAN), showing significant efficacy in slowing disease progression [1][2][8] - Fabhalta received accelerated approval in the U.S. in August 2024 for reducing proteinuria in adults with IgAN at risk of rapid disease progression [1] - The positive study results will support Novartis' regulatory submission for traditional FDA approval in 2026 [3][8] Drug Approvals and Pipeline - Fabhalta has received FDA and European Commission approval for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) and is also approved in China for IgAN [4] - The drug is being evaluated for various rare kidney diseases, including atypical hemolytic uremic syndrome and lupus nephritis [5] - Novartis' portfolio includes other candidates like Vanrafia (atrasentan) and zigakibart for IgAN [5] Competitive Landscape - Travere Therapeutics' Filspari (sparsentan) is also approved for slowing kidney function decline in adults with primary IgAN [5][6] - Filspari received full approval in September 2024 based on long-term results from the PROTECT study [6] Financial Performance and Strategic Moves - Novartis has shown strong performance, with shares gaining 36.7% year-to-date compared to the industry's 7.5% growth [9] - The company is focused on strategic acquisitions, including the planned acquisition of Tourmaline Bio, Inc. for $1.4 billion, which will enhance its cardiovascular pipeline [11][12] - Novartis aims to strengthen its pipeline through both organic growth and acquisitions [11]

Core Insights - The Russell 2000 index has rebounded significantly in Q3 2025, achieving its first all-time high since November 2021, driven by interest-rate-cut expectations and overall optimism in U.S. equities [1] - Nearly 60% of the Russell 2000 index components are trading above their 200-day moving average, indicating potential for further gains [2] - Notable top performers in the Russell 2000 index include Mercurity Fintech Holding, which surged by 538.44% over the past three months, and other companies showing substantial growth [4] Performance Highlights - The top performers in the Russell 2000 for Q3 include: - Mercurity Fintech Holding MFH (+538.44%) - Better Home & Finance Holdings BETR (+353%) - Kodiak Sciences KOD (+338.87%) - Korro Bio KRRO (+283.43%) - Celcuity CELC (+270.04%) - Bloom Energy BE (+253.55%) - American Battery Technology ABAT (+200%) [4] - Year-to-date best performers include: - Oncology Institute TOI (+1,029.45%) - Thredup TDUP (+579.86%) - Better Home & Finance Holdings BETR (+529.37%) - Oklo OKLO (+425.81%) - Palvella Therapeutics PVLA (+422.42%) [4][5]

Group 1: Major Acquisitions - Electronic Arts (EA) is being acquired by a consortium including Saudi Arabia's Public Investment Fund (PIF), Silver Lake, and Affinity in a $55 billion deal, valuing the company at approximately $210 per share [3][8] - Novartis AG has launched a tender offer to acquire all outstanding shares of Tourmaline Bio for $48 per share in cash, with a total transaction value of approximately $1.4 billion [4][8] Group 2: Market Sentiment and Economic Concerns - Fears of a potential U.S. government shutdown are driving investors towards safe-haven assets, resulting in a firming of U.S. Treasuries and pushing U.S. gold reserves to a record $1 trillion [5][8] - Federal Reserve Governor Christopher Waller has advocated for an open approach to new payment technologies, including stablecoins, emphasizing the need for consumer safety guardrails [6][8] Group 3: Corporate Developments - Chipotle Mexican Grill plans to introduce a new Red Chimichurri sauce in the U.S. and Canada, expanding its menu offerings [9] - ASML Holding received an upgrade to "Buy" from Mizuho, supported by positive spending trends affecting its earnings outlook [9] - Moody's maintained JLR's BA1 credit rating but shifted its outlook to negative due to a significant cyber disruption [9] Group 4: IPO Activity - Fermi Inc. has announced plans to sell 32.5 million shares of common stock in an Initial Public Offering (IPO) [7][8]

Acquisition Announcement - Novartis has initiated a tender offer to acquire all outstanding shares of Tourmaline Bio, Inc. at a price of $48 per share in cash [1] - The tender offer is part of a previously announced Merger Agreement dated September 8, 2025 [1] Offer Details - The tender offer will expire on October 27, 2025, unless extended or terminated earlier [2] - Novartis filed a tender offer statement with the SEC, detailing the terms and conditions of the offer [3] Conditions of the Offer - The obligation to purchase shares is subject to customary conditions, including regulatory approvals and the tender of a majority of shares [4] - The offer is not contingent on financing [4] Information Agents - Innisfree M&A Incorporated is acting as the information agent for the offer, while Computershare Trust Company, N.A. serves as the depositary and paying agent [5] Regulatory Filings - Tourmaline's board of directors has recommended that stockholders accept the offer and tender their shares [3] - Both Novartis and Tourmaline have filed necessary documents with the SEC, which are available for public access [6][8]

Accessibility StatementSkip Navigation Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recog ...

Core Viewpoint - Novartis is set to acquire Tourmaline Bio, Inc. for $1.4 billion, enhancing its cardiovascular pipeline with the addition of pacibekitug, an anti-IL-6 monoclonal antibody targeting atherosclerotic cardiovascular disease (ASCVD) [1][3][7] Acquisition Details - Novartis will pay $48 per share in cash to Tourmaline shareholders, with the transaction expected to close in the fourth quarter of 2025 [3][7] - The acquisition aligns with Novartis' strategy to expand its pipeline through strategic acquisitions [9] Product Information - Pacibekitug is designed to mitigate systemic inflammation in ASCVD and has shown high affinity binding to IL-6, a key cytokine in systemic inflammation [4][7] - Phase II TRANQUILITY study results indicated that pacibekitug reduced median high-sensitivity C-reactive protein (hs-CRP) levels by 85% to 86% with safety profiles comparable to placebo [5][7] Market Reaction - Following the announcement of the acquisition and promising study results, shares of Tourmaline Bio surged by 57.8% [4][8] Strategic Focus - Novartis has been actively pursuing acquisitions to strengthen its pipeline, including a recent licensing agreement with Arrowhead Pharmaceuticals for ARO-SNCA [9][10] - The company also acquired Regulus Therapeutics for $0.8 billion, with potential additional payments of $0.9 billion based on regulatory milestones [11]

Market Overview - US stocks reached new record highs, with the Dow Jones Industrial Average closing above 45,725, the S&P 500 above 6,512, and the Nasdaq Composite marking its second consecutive closing high this week [1] Labor Market Data - The Bureau of Labor Statistics reported that the US economy likely added 911,000 fewer jobs than previously estimated for the 12-month period ending March 2025, a larger revision than the expected 680,000 [2] Federal Reserve Expectations - The labor market data has heightened discussions on how the Federal Reserve will respond, with traders anticipating an interest-rate cut in the upcoming meeting. The focus has shifted to the potential magnitude of the cut and its implications for the stock market [3] Inflation Reports - Key inflation data, including the producer price index (PPI) and consumer price index (CPI), are set to be released, which will provide insights into whether rising prices could hinder significant interest-rate cuts [4] Corporate Highlights - Apple's annual fall event showcased new products, including the iPhone 17 and new AirPods, but its stock fell approximately 1.5% [5] - Tourmaline Bio and Nebius shares surged over 50% following deal announcements with Novartis and Microsoft, respectively [5] - Oracle and GameStop are scheduled to report earnings after market close [5]